A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 28 Oct 2017
At a glance
- Drugs Nazartinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 19 Oct 2017 Planned End Date changed from 25 Jul 2019 to 20 Sep 2019.
- 15 Jun 2017 Planned primary completion date changed from 25 Jul 2019 to 11 Feb 2018.
- 10 Jun 2017 Biomarkers information updated